These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 29475959)

  • 21. Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.
    Zhang C; Stelloo E; Barrans S; Cucco F; Jiang D; Tzioni MM; Chen Z; Li Y; Swennenhuis JF; Makker J; Rásó-Barnett L; Liu H; El-Daly H; Soilleux E; Shah N; Nagumantry SK; Kyaw M; Prahladan MP; Tooze R; Westhead DR; Feitsma H; Davies AJ; Burton C; Johnson PWM; Du MQ
    Leukemia; 2024 Mar; 38(3):621-629. PubMed ID: 38184753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population.
    Alduaij W; Collinge B; Ben-Neriah S; Jiang A; Hilton LK; Boyle M; Meissner B; Chong L; Miyata-Takata T; Slack GW; Farinha P; Craig JW; Lytle A; Savage KJ; Villa D; Gerrie AS; Freeman CL; Gascoyne RD; Connors JM; Morin RD; Sehn LH; Mungall AJ; Steidl C; Scott DW
    Blood; 2023 May; 141(20):2493-2507. PubMed ID: 36302166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting.
    Thirunavukkarasu B; Bal A; Prakash G; Malhotra P; Singh H; Das A
    Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):49-55. PubMed ID: 34456240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The incidence of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in diffuse large B-cell lymphoma].
    Li M; Zhang QL; Zhao W; Huang X; Gong LP; Shi QF; Liu CL; Gao ZF
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):124-128. PubMed ID: 33858042
    [No Abstract]   [Full Text] [Related]  

  • 25. Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
    Stengel A; Kern W; Meggendorfer M; Haferlach T; Haferlach C
    Br J Haematol; 2019 Jun; 185(5):951-954. PubMed ID: 30460680
    [No Abstract]   [Full Text] [Related]  

  • 26. Inferior survival in high-grade B-cell lymphoma with
    McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
    Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.
    Sesques P; Johnson NA
    Blood; 2017 Jan; 129(3):280-288. PubMed ID: 27821509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-Grade B-Cell Lymphoma (HGBL) with
    Tsai CC; Su YC; Bamodu OA; Chen BJ; Tsai WC; Cheng WH; Lee CH; Hsieh SM; Liu ML; Fang CL; Lin HT; Chen CL; Yeh CT; Lee WH; Ho CL; Lai SW; Tzeng HE; Hsieh YY; Chang CL; Zheng YM; Liu HW; Yen Y; Whang-Peng J; Chao TY
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33807449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements.
    Monika F; Sabri A; Cantu D; Vail E; Siref A
    J Hematop; 2024 Sep; 17(3):155-161. PubMed ID: 38914869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma.
    Alsuwaidan A; Koduru P; Fuda F; Manuel Jaso J; Chen M; Rosado F; Luu HS; Sweed N; Garcia R; Doucet M; Desai NB; Kumar KA; Awan FT; Ramakrishnan Geethakumari P; Chen W
    Am J Clin Pathol; 2022 Sep; 158(3):338-344. PubMed ID: 35511691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6).
    Witte HM; Riedl J; Künstner A; Fähnrich A; Ketzer J; Fliedner SMJ; Reimer N; Bernard V; von Bubnoff N; Merz H; Busch H; Feller A; Gebauer N
    Target Oncol; 2023 Sep; 18(5):749-765. PubMed ID: 37488307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs.
    Marino FZ; Aquino G; Brunelli M; Scognamiglio G; Pedron S; Ronchi A; Cozzolino I; Sparano L; Botti G; Panico L; De Chiara A; Franco R;
    Virchows Arch; 2021 Sep; 479(3):565-573. PubMed ID: 33768318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics and Clinical Value of MYC , BCL2, and BCL6 Rearrangement Detected by Next-generation Sequencing in DLBCL.
    Zeng Y; Wei R; Bao L; Xue T; Qin Y; Ren M; Bai Q; Yao Q; Yu C; Chen C; Wei P; Yu B; Cao J; Li X; Zhang Q; Zhou X
    Am J Surg Pathol; 2024 Aug; 48(8):919-929. PubMed ID: 38937822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated Genomic DNA/RNA Profiling vs Fluorescence in Situ Hybridization in the Detection of MYC and BCL2 (and BCL6) Rearrangements in Large B-Cell Lymphomas: Updates Amid the New WHO Classification of Lymphoid Neoplasms.
    de Lima Guido LP; Chapman J; Cassidy DP
    Am J Clin Pathol; 2023 Jul; 160(1):41-48. PubMed ID: 36881639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study).
    Hilton LK; Collinge B; Ben-Neriah S; Alduaij W; Shaalan H; Weng AP; Cruz M; Slack GW; Farinha P; Miyata-Takata T; Boyle M; Meissner B; Cook JR; Ondrejka SL; Ott G; Rosenwald A; Campo E; Amador C; Greiner TC; Raess PW; Song JY; Inghirami G; Jaffe ES; Weisenburger DD; Chan WC; Beiske K; Fu K; Delabie J; Pittaluga S; Iqbal J; Wright G; Sehn LH; Savage KJ; Mungall AJ; Feldman AL; Staudt LM; Steidl C; Rimsza LM; Morin RD; Scott DW
    Blood; 2024 Aug; 144(5):525-540. PubMed ID: 38701426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.
    Pina-Oviedo S; Bellamy WT; Gokden M
    Ann Diagn Pathol; 2020 Oct; 48():151610. PubMed ID: 32889391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
    Miyaoka M; Kikuti YY; Carreras J; Ikoma H; Hiraiwa S; Ichiki A; Kojima M; Ando K; Yokose T; Sakai R; Hoshikawa M; Tomita N; Miura I; Takata K; Yoshino T; Takizawa J; Bea S; Campo E; Nakamura N
    Mod Pathol; 2018 Feb; 31(2):313-326. PubMed ID: 28984304
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Tourneret A; Alame M; Rigau V; Bauchet L; Fabbro M; De Oliveira L; Cacheux V; Costes V; Lacheretz-Szablewski V
    J Clin Pathol; 2021 Oct; 74(10):650-656. PubMed ID: 32912960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.
    Hilton LK; Tang J; Ben-Neriah S; Alcaide M; Jiang A; Grande BM; Rushton CK; Boyle M; Meissner B; Scott DW; Morin RD
    Blood; 2019 Oct; 134(18):1528-1532. PubMed ID: 31527075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.